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Abstract
Background: Hepatitis B core antibody (HBcAb)-positive graft is reported to cause de novo hepatitis B after liver
transplantation with a probability of 38–100 % without prophylaxis. Hepatitis B surface antigen loss is reported to
be achieved with a probability of only 3–8 % in the patients treated by antiviral agents. We present an
extremely rare case of spontaneous resolution of de novo hepatitis B after living donor liver transplantation
(LDLT) with HBcAb-positive graft.
Case presentation: An 8-year-old female patient underwent LDLT for end-stage biliary atresia using an
HBcAb-positive left lobe graft. After transplantation, she did not receive any prophylactic agents for hepatitis
B. Two years after LDLT, she was diagnosed with chronic hepatitis B. Six years after LDLT, liver fibrosis and
hepatitis activity were advanced and lamivudine was started. Two years after lamivudine administration,
emergence of a lamivudine-resistant YMDD mutant was detected and adefovir dipivoxil was combined with
lamivudine. Hepatitis B virus deoxyribonucleic acid (HBV-DNA) became undetectable soon after the addition of
adefovir dipivoxil. Twelve years after transplantation, acute rejection occurred and steroid pulse therapy was
performed, but hepatitis B did not become severe and HBV-DNA continued to be undetectable. Fifteen years
after LDLT, she voluntarily discontinued medication of all drugs, including immunosuppressive agents and antiviral
drugs for 1 year because of mental instability. After an interval of 1 year, liver function was normal and her serological
HBV status was as follows: HBsAg(−), HBsAb(+), HBeAb(−), HBeAb(+), HBcAb(+) and HBV-DNA(−). From these results, we
diagnosed her condition as spontaneous clearance of de novo hepatitis B. The patient is free of antiviral therapies and
continues to take a low dose of immunosuppressive drugs and is leading a normal life.
Conclusions: In this case, HBsAg loss is finally achieved but we need to follow carefully for HBV reactivation with the
fibrosis of the graft in mind.
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Background
Liver transplantation is the standard treatment for vari-
ous end-stage liver diseases and acute liver failure. To
resolve the organ shortage, hepatitis B core antibody
(HBcAb)-positive graft is used in Japan. The HBcAb-
positive graft is reported to cause de novo hepatitis B
after liver transplantation with a probability of 38–100 %
without prophylaxis [1, 2]. The combination of hepatitis
B immunoglobulin (HBIG) and nucleoside analogue,
such as lamivudine and entecavir, markedly prevents the
onset of de novo hepatitis B after liver transplantation
using HBcAb-positive grafts [3, 4].
Serum hepatitis B virus deoxyribonucleic acid (HBV-
DNA) level is well correlated with the incidence of hepa-
tocellular carcinoma (HCC) [5, 6]. Antiviral therapies,
including nucleoside analogue, lead to sustained viral
suppression, which leads to the prevention of cirrhosis
and HCC [7–9]. Serologic resolution of HBV infection is
ideally defined as the loss of hepatitis B surface antigen
(HBsAg), seroconversion to hepatitis B surface antibody
(HBsAb), and undetectable serum HBV-DNA [10], but
HBsAg loss is reported to be achieved with a probability
of only 3–8 % in the patients treated by antiviral agents
[11, 12]. Current antiviral therapies aim for long-term
virological control, and serologic resolution of HBV is
rarely achieved.
We report an extremely rare case of spontaneous reso-
lution of de novo HBV after living donor liver trans-
plantation using an HBcAb-positive graft.
Case presentation
A 91-day-old female patient had undergone Kasai’s oper-
ation for biliary atresia (BA). After the operation, liver
failure gradually advanced and she was diagnosed with
liver cirrhosis at 8 years old. All hepatitis B serological
markers before transplantation, including HBV-DNA,
HBsAg and HBsAb, were negative (Table 1). The donor
was her mother and the donor’s pre-transplant HBV
status was as follows: HBsAg(−), HBsAb(+), hepatitis
B envelope antigen (HBeAg(−)), hepatitis B envelope
antibody (HBeAb(+)) and HBcAb(+).
She underwent living donor liver transplantation
(LDLT) for end-stage BA using an HBcAb-positive left
lobe graft and began an immunosuppression regimen of
cyclosporine A (CsA) and steroid. After transplantation,
she did not receive HBIG prophylaxis because it was not
well known that the HBcAb-positive graft was a risk fac-
tor for hepatitis B at that time.
Two years after LDLT, the hepatitis B markers were
changed as follows: HBsAg(+), HBeAg(+), HBeAb(−)
and HBV-DNA(+), and she was diagnosed with chronic
hepatitis B (Fig. 1). Other liver functions were normal,
and she was followed closely without antiviral treatment.
Six years after LDLT, the level of transaminases in-
creased and liver biopsy was performed. From the results
of the pathological findings, liver fibrosis and hepatitis
activity were advanced (Fig. 2a, b) and lamivudine was
started. HBV-DNA became undetectable soon after the
start of the antiviral treatment, and the liver function
continued to be at a normal level for several years. Two
years after lamivudine administration, the serum HBV-
DNA level became detectable again and emergence of a
lamivudine-resistant YMDD mutant (YIDD) was detected.
Adefovir dipivoxil was combined with lamivudine. HBV-
DNA became undetectable soon after the addition of
adefovir dipivoxil. Liver biopsies, which were performed
during the period, showed improvement of the liver
fibrosis and hepatitis activity (Fig. 2c, d).
Twelve years after transplantation, acute rejection oc-
curred and steroid pulse therapy (250 mg/day, 3 days)
was performed. Hepatitis B did not become severe, and
HBV-DNA continued to be undetectable during and
after the treatment for acute rejection.
Fifteen years after LDLT, she had obsessive thoughts
and suddenly stopped a routine visit and voluntarily dis-
continued medication of all drugs, including immuno-
suppressive agents and antiviral drugs for 1 year. During
the period, there were no episodes of severe hepatitis
and rejection.
She visited our hospital after an interval of 1 year.
Mental status was relatively stable and liver function was
normal, and her serological HBV status was as follows
Table 1 Change of hepatitis B serological markers in the clinical course
Recipient Donor












HBsAg (IU/ml) 0.29 99.9 >2000.0 >2000.0 146.9 177.6 0.01 0.25
HBsAb (mIU/ml) 0.26 0.0 0.3 0.1 5.0 5.0 19.2 35.46
HBeAg − + + + + + − −
HBeAb − − − − − − − −
HBcAb − + + + + + + +
HBV-DNA
(log copies/ml)
<2.6 >7.6 <2.6 <2.6 <2.6 <2.6 <2.1 <2.6
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(Table 1): HBsAg(−), HBsAb(+), HBeAb(−), HBeAb(−),
HBcAb(+) and HBV-DNA(−). From these results, we di-
agnosed her condition as a spontaneous clearance of de
novo hepatitis B. The patient is free of antiviral therapies
and continues to take a low dose of immunosuppressive
drugs (CsA and steroid) and is leading a normal life.
Discussion
The HBcAb-positive graft is reported to cause de novo
hepatitis B after liver transplantation with a probability
of 38–100 % [1, 2]. This case received no prophylaxis
after transplantation, because it was not well known at
the time of liver transplantation that the HBcAb-positive
Fig. 1 Major events and treatments in the clinical course. The panel shows a timeline of the clinical course after liver transplantation. The periods
of antiviral agents and immunosuppressive drugs are shown by the grey bars. LAM lamivudine, ADV adefovir dipivoxil
Fig. 2 Pathological findings of liver biopsy specimens. a, b Liver tissue before the treatment of de novo hepatitis B (a HE stain ×100,
b HE stain ×400). Lymphocytic invasion to Glisson’s capsule and piecemeal necrosis were shown. c, d Liver tissue after lamivudine and
adefovir dipivoxil therapy (c HE stain ×100, d HE stain ×400). Mild invasion of lymphocyte was shown, and liver fibrosis and the activity
of hepatitis B were significantly improved
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graft was a high risk factor for de novo hepatitis B. Now,
in our institution, pre-transplant HBsAg-negative recipi-
ents, who received HBcAb-positive grafts, have prophy-
lactic therapies with an injection of high doses of
hepatitis B immunoglobulin (HBIG) and administration
of nucleoside analogue, and de novo hepatitis B did not
occur in two pre-transplant HBsAg-negative recipients
using HBcAb-positive grafts who received prophylactic
therapies [13].
Viral persistence depends on the balance between viral
replication and host immune responses. Immunosup-
pression regimen of CsA and steroid was continuously
given after transplantation, and liver function was nor-
mal for 6 years. In this period, viral replication became
persistent but active hepatitis might disappear due to
host immature immunity and immunosuppressive
agents. As the patient grew up, host immunity improved
and the immune system might be able to destroy HBV-
infected hepatocytes, causing hepatitis. Steroids are a
well-known risk factor of HBV reactivation, especially
when the dose is equivalent to 20 mg/day [14]. In this
case, steroid pulse therapy (250 mg/day, 3 days) was per-
formed for rejection at 18 years after transplantation but
HBV reactivation had not occurred, which might be con-
tributed to the inhibition of viral replication by antiviral
agents. An acute cellular rejection was reported to have
possibilities to evoke antiviral response in cases of hepa-
titis C virus-positive recipients and might be involved in
the spontaneous resolution of HBV [15].
Most initial HBV infections in adulthood result in
complete recovery with HBsAg loss and the production
of HBsAb. In this case, hepatitis markers had finally
changed as follows: HBsAg loss, seroconversion to anti-
HBs antibody and sustained suppression of HBV-DNA.
Voluntary cessation of immunosuppressive agents re-
sulted in the normalization of host immunity, and the
infectious status of HBV was thought to change into the
so-called “initial infection in adulthood”. Spontaneous
clearance of HBV had happened fortunately without
becoming fulminant hepatitis. The administration of
antiviral agents until the cessation of drugs suppressed
viral replication, which might contribute to the prevention
of fulminant hepatitis.
HBsAg loss is rare with a probability of only 3–8 % in
the patients treated by antiviral agents [11, 12], and
HBsAg levels are reported to correlate well with the
intrahepatic covalently closed circular DNA (cccDNA)
level [16, 17]. We think that the definition of the spontan-
eous resolution of de novo hepatitis B is the serological
HBV status: HBsAg(−) and HBV-DNA(−). Despite sero-
logical resolution, HBV cccDNA remains in hepatocytes
and circulating peripheral mononuclear cells [18, 19]. The
necessary conditions of the cessation of antiviral therapy
were reported [20, 21], and we think that the cessation of
antiviral therapy could be performed safely if the sero-
logical HBV status is HBV-DNA(−), HBeAg(−) and/or
HBsAg(−). This case fulfilled the necessary conditions and
stopped antiviral therapy, but a low dose of immunosup-
pressive drugs was administered in order to prevent rejec-
tion and the fibrosis of the graft.
Conclusions
We present an extremely rare case of the spontaneous
resolution of de novo hepatitis B after LDLT with an
HBcAb-positive graft. HBsAg loss is finally achieved, but
we need to follow the patient carefully for HBV reactiva-
tion with the fibrosis of the graft in mind.
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